Sequence variants of NAT1 and NAT2 and other xenometabolic genes and risk of lung and aerodigestive tract cancers in Central Europe

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 1, 2008, Pages 141-147

  McKay, James D ^a   Hashibe, Mia ^a   Hung, Rayjean J ^a,c   Wakefield, Jon ^a   Gaborieau, Valerie ^a   Szeszenia Dabrowska, Neonila ^d   Zaridze, David ^e   Lissowska, Jolanta ^f   Rudnai, Peter ^g   Fabianova, Eleonora ^h   Mates, Dana ⁱ   Foretova, Lenka ^j   Janout, Vladimir ^k   Bencko, Vladimir ^l   Chabrier, Amelie ^a   Hall, Janet ^a   Boffetta, Paolo ^a   Canzian, Federico ^b   Brennan, Paul ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

^e N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^f INSTITUTE OF ONCOLOGY   (Poland)

^g NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH   (Hungary)

^h Specialized Institute of Hygiene and Epidemiology   (Slovakia)

ⁱ NATIONAL INSTITUTE OF PUBLIC HEALTH   (Romania)

^j MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^k PALACKÝ UNIVERSITY   (Czech Republic)

^l CHARLES UNIVERSITY   (Czech Republic)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE;

ADULT; AGED; ARTICLE; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; EASTERN EUROPE; EUROPE; FEMALE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENETICS; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; HYPOTHESIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METABOLISM; PRIORITY JOURNAL; RISK; SMOKING; STATISTICAL SIGNIFICANCE;

EID: 38849165856     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0553     Document Type: Article

References (21)

1. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000;321:323-9.
2. Bartsch H, Nair U, Risch A, Rojas M, Wikman H, Alexandrov K. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 2000;9:3-28.
3. Hein DW, Doll MA, Fretland AJ, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000;9:29-42.
4. Ho T, Wei Q, Sturgis EM. Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neck. Head Neck 2007;29:682-99.
5. Garcia-Closas M, Malats N, Silverman D, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005;366:649-59.
6. Hein DW. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 2002;506-507:65-77.
7. Scelo G, Constantinescu V, Csiki I, et al. Occupational exposure to vinyl chloride, acrylonitrile and styrene and lung cancer risk (Europe). Cancer Causes Control 2004;15:445-52.
8. Stram DO, Haiman CA, Hirschhorn JN, et al. Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 2003;55:27-36.
9. Wikman H, Thiel S, Jager B, et al. Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility. Pharmacogenetics 2001;11:157-68.
10. Landi S, Gemignani F, Moreno V, et al. A comprehensive analysis of phase I, phase II metabolism gene polymorphisms and risk of colorectal cancer. Pharmacogenet Genomics 2005;15:535-46.
11. Gemignani F, Landi S, Szeszenia-Dabrowska N, et al Development of lung cancer before the age of 50: the role of xenobiotic metabolism genes. Carcinogenesis 2007;28:1287-93.
12. Wakefield JA. Bayesian measure of the probability of false discovery in genetic epidemiology studies. Am J Hum Genet 2007;81:208-27.
13. Moslehi R, Chatterjee N, Church TR, et al. Cigarette smoking, N-acetyltransferase genes and the risk of advanced colorectal adenoma. Pharmacogenomics 2006;7:819-29.
14. Hein DW. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 2006;25:1649-58.
15. Boukouvala S, Sim E. Structural analysis of the genes for human arylamine N-acetyltransferases and characterisation of alternative transcripts. Basic Clin Pharmacol Toxicol 2005;96:343-51.
16. Sim E, Payton M, Noble M, Minchin R. An update on genetic, structural and functional studies of arylamine N-acetyltransferases in eucaryotes and procaryotes. Hum Mol Genet 2000;9:2435-41.
17. Borlak J, Reamon-Buettner SM. N-acetyltransferase 2 (NAT2) gene polymorphisms in colon and lung cancer patients. BMC Med Genet 2006;7:58.
18. Bell DA, Badawi AF, Lang NP, Ilett KF, Kadlubar FF, Hirvonen A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 1995;55:5226-9.
19. Bouchardy C, Mitrunen K, Wikman H, et al. N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk. Pharmacogenetics 1998;8:291-8.
20. Perera FP, Tang D, Brandt-Rauf P, et al. Lack of associations among cancer and albumin adducts, ras p21 oncoprotein levels, and CYP1A1, CYP2D6, NAT1, and NAT2 in a nested case-control study of lung cancer within the physicians' health study. Cancer Epidemiol Biomarkers Prev 2006;15:1417-9.
21. Abdel-Rahman SZ, El-Zein RA, Zwischenberger JB, Au WW. Association of the NAT1*10 genotype with increased chromosome aberrations and higher lung cancer risk in cigarette smokers. Mutat Res 1998;398:43-54.